Enliven Therapeutics Inc.

19.93
1.05 (5.56%)
At close: Apr 02, 2025, 3:59 PM
19.56
-1.82%
After-hours: Apr 02, 2025, 04:35 PM EDT

Enliven Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Revenue n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue n/a 297K 622K 99K 97K 33K n/a n/a
Gross Profit n/a -297K -622K -99K -97K -33K n/a n/a
Operating Income -104.55M -83.53M -38.79M -24.76M -9.32M -24.12M -10.68M -8.9M
Interest Income 14.89M 11.97M 1.13M 22K 31K 578K n/a n/a
Pretax Income -89.26M -71.58M -37.66M -24.74M -18.97M -23.46M -11.34M 221K
Net Income -89.02M -71.58M -37.75M -24.72M -18.93M -23.46M -11.34M n/a
Selling & General & Admin 23.78M 18.95M 7.77M 4.29M 1.08M 5.07M 2.44M 987K
Research & Development 80.78M 64.57M 31.02M 20.47M 8.24M 19.01M 8.24M 7.92M
Other Expenses n/a n/a n/a n/a -9.68M n/a n/a n/a
Operating Expenses 104.55M 83.53M 38.79M 24.76M 9.32M 24.08M 10.68M 8.9M
Interest Expense n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses n/a n/a n/a n/a n/a -33K n/a n/a
Cost & Expenses n/a 83.53M 38.79M 24.76M 9.32M 24.12M 10.68M 8.9M
Income Tax -232K n/a 88K -22K -31K 653K -821.14K 221K
Shares Outstanding (Basic) 47.07M 35.55M 6.25M 7.81M 3.48M 4.32M 4.32M 4.32M
Shares Outstanding (Diluted) 47.07M 35.55M 6.25M 7.81M 3.48M 4.32M 4.32M 4.32M
EPS (Basic) -1.89 -2.01 -6.03 -3.17 -14.14 -5.43 -2.62 n/a
EPS (Diluted) -1.89 -2.01 -6.03 -3.17 -14.14 -5.43 -2.62 n/a
EBITDA -104.55M -81.93M -38.58M -24.65M -9.27M -23.43M -11.34M 221K
EBIT n/a -82.23M -38.79M -24.76M -9.32M -23.46M -11.34M 221K
Depreciation & Amortization n/a 297K 215K 115K 97K 33K -660K n/a